After a major facelift, AltruBio says it's ready for a pivotal fight against graft-versus-host disease
AltruBio got a makeover, and now it’s ready for its closeup.
CEO Judy Chou took over last January — when the biotech was still known as AbGemomics — on a mission to rebuild and rebrand. She culled the company’s oncology program to laser in on an old immunology candidate. Now with a new board, a new name and new cash, the company has its eyes set on a pivotal study.
On Thursday, AltruBio unveiled a $63 million Series A round to fund its transformation. Its lead candidate, neihulizumab (also known as AbGn-168H), is an immune checkpoint regulator targeting PSGL-1, a glycoprotein found on white blood cells and endothelial cells. Earlier this month, the Phase Ib candidate nabbed FDA fast track designation in steroid refractory acute graft-versus-host disease (SR-aGVHD).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.